Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 33, Issue 3, 2014, Pages 397-402

  Ji, Hye In ^a   Lee, Sang Hoon ^b   Song, Ran ^b   Yang, Hyung In ^b   Lee, Yeon Ah ^c   Hong, Seung Jae ^c   Kim, Somi ^c   Park, Yong Beom ^d   Lee, Soo Kon ^d   Yoo, Myung Chul ^a   Kim, Kyoung Soo ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Disease modifying antirheumatic drugs (DMARDs); Osteopontin (OPN); Rheumatoid arthritis (RA); TNF blocker

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; OSTEOPONTIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; DAS28; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OSTEOPONTIN; SEVERITY OF ILLNESS INDEX;

EID: 84896488601     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2375-3     Document Type: Article

References (23)

1. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7(6):429-442 (Pubitemid 46834849)
2. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O (2011) What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 7(9):528-536
3. Zheng W, Li R, Pan H, He D, Xu R, Guo TB, Guo Y, Zhang JZ (2009) Role of osteopontin in induction ofmonocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60(7):1957-1965
4. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, Ni L, Zhang D, Li N, Zhang J (2005) Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32(3):410-416 (Pubitemid 40381409)
5. Braitch M, Constantinescu CS (2010) The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflamm Allergy Drug Targets 9(4):249-256
6. Frenzel DF, Weiss JM (2011) Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy. Expert Rev Clin Immunol 7(1):93-109
7. Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M (2010) Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev 18(3):125-131
8. Scatena M, Liaw L, Giachelli CM (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27(11):2302-2309 (Pubitemid 350203943)
9. Hasegawa M, Nakoshi Y, Iino T, Sudo A, Segawa T, Maeda M, Yoshida T, Uchida A (2009) Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol 36(2):240-245
10. Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19(5-6):333-345
11. Morimoto J, Kon S, Matsui Y, Uede T (2010) Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets 11(4):494-505
12. Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, De Martino M, Brandi ML, Falcini F (2009) Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis. J Rheumatol 36(10):2308-2313
13. Straburzynska-Lupa A, Nowak A, Romanowski W, Korman P, Pilaczynska-Szczesniak L (2013) A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis. J Bone Miner Metab 31(2):169-176
14. Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK (2008) Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 47(12):1775-1779
15. Jacobs JP, Pettit AR, Shinohara ML, Jansson M, Cantor H, Gravallese EM, Mathis D, Benoist C (2004) Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis Rheum 50(8):2685-2694 (Pubitemid 39062732)
16. Ishii T, Ohshima S, Ishida T, Mima T, Tabunoki Y, Kobayashi H, MaedaM, Uede T, Liaw L, Kinoshita N et al (2004) Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun 316(3):809-815 (Pubitemid 38368024)
17. Boumans MJ, Houbiers JG, Verschueren P, Ishikura H, Westhovens R, Brouwer E, Rojkovich B, Kelly S, den Adel M, Isaacs J et al (2012) Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann Rheum Dis 71(2):180-185
18. Gao SG, Li KH, Zeng KB, Tu M, Xu M, Lei GH (2010) Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage 18(1):82-87
19. Honsawek S, Tanavalee A, Sakdinakiattikoon M, Chayanupatkul M, Yuktanandana P (2009) Correlation of plasma and synovial fluid osteopontin with disease severity in knee osteoarthritis. Clin Biochem 42(9):808-812
20. Naldini A, Leali D, Pucci A, Morena E, Carraro F, Nico B, Ribatti D, Presta M (2006) Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol 177(7):4267-4270 (Pubitemid 44469753)
21. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16(2):79-87 (Pubitemid 43247403)
22. Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, Ludvik B, Silberhumer GR, Prager G et al (2008) Osteopontin expression in human andmurine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 149(3):1350-1357 (Pubitemid 351397930)
23. Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, Silva C, Rotellar F, Mugueta C, Gil MJ, Cienfuegos JA et al (2007) Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 92(9):3719-3727 (Pubitemid 47435361)